InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery
19 févr. 2024 02h00 HE
|
InveniAI LLC
Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...
InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
04 avr. 2023 08h43 HE
|
InveniAI LLC
Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...
InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration
31 mai 2022 08h15 HE
|
InveniAI LLC
GUILFORD, Conn. and TOKYO, May 31, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery...
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools
24 févr. 2022 12h39 HE
|
InveniAI LLC
GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
16 déc. 2021 08h10 HE
|
InveniAI LLC
Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
20 juil. 2021 08h10 HE
|
InveniAI LLC
- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
06 juil. 2021 08h10 HE
|
InveniAI LLC
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early...
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
11 mai 2021 08h10 HE
|
InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
27 avr. 2021 08h10 HE
|
InveniAI LLC
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified...
InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration
09 déc. 2020 08h10 HE
|
InveniAI
Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technologyKyowa Kirin will select multiple programs...